Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting.

By A. Nauta, Geert Westerhuis, A. Kruisselbrink, Ellie G. A. Lurvink, R. Willemze, W. Fibbe. Blood, 2006

726 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Different populations and sources of human mesenchymal stem cells (MSC): A comparison of adult and neonatal tissue-derived MSC (2011, result): “Although most of the studies revealed MSC to be immunosuppressive, Nauta et al found in mice that donor-derived MSC are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting [100].”
Mesenchymal stem cells and immunomodulation: current status and future prospects (2016, background): “MSCs has been reported to lead to alloimmunization and subsequent refractoriness in mice.(128,129) These issues need to be addressed in the future design of clinical trials.”
Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity (2009, background): “Other recent work has challenged the in vivo immunoprivileged state of MSCs, asserting that they exert a delayed host response 2 weeks posttransplantation (32, 33).”
Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. (2008, background): “Previous studies by various groups have had variable results in demonstrating immunosuppression by MSCs ( Nauta et al., 2006; Sudres et al., 2006).”